- Home
- OMH vs GNPX Comparison
OMH vs GNPX Comparison
Compare OMH & GNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OMH
- GNPX
- Stock Information
- Founded
- OMH 2015
- GNPX 2009
- Country
- OMH Singapore
- GNPX United States
- Employees
- OMH N/A
- GNPX N/A
- Industry
- OMH Real Estate
- GNPX Biotechnology: Pharmaceutical Preparations
- Sector
- OMH Finance
- GNPX Health Care
- Exchange
- OMH Nasdaq
- GNPX Nasdaq
- Market Cap
- OMH N/A
- GNPX 6.1M
- IPO Year
- OMH 2023
- GNPX 2018
- Fundamental
- Price
- OMH $2.55
- GNPX $0.38
- Analyst Decision
- OMH Strong Buy
- GNPX Strong Buy
- Analyst Count
- OMH 1
- GNPX 1
- Target Price
- OMH $15.00
- GNPX $10.00
- AVG Volume (30 Days)
- OMH 17.0K
- GNPX 6.0M
- Earning Date
- OMH 01-01-0001
- GNPX 05-13-2025
- Dividend Yield
- OMH N/A
- GNPX N/A
- EPS Growth
- OMH N/A
- GNPX N/A
- EPS
- OMH N/A
- GNPX N/A
- Revenue
- OMH $5,390,607.00
- GNPX N/A
- Revenue This Year
- OMH $111.47
- GNPX N/A
- Revenue Next Year
- OMH $32.08
- GNPX N/A
- P/E Ratio
- OMH N/A
- GNPX N/A
- Revenue Growth
- OMH 25.77
- GNPX N/A
- 52 Week Low
- OMH $0.25
- GNPX $0.22
- 52 Week High
- OMH $2.70
- GNPX $4.09
- Technical
- Relative Strength Index (RSI)
- OMH 63.16
- GNPX 43.09
- Support Level
- OMH $2.12
- GNPX $0.22
- Resistance Level
- OMH $2.31
- GNPX $0.39
- Average True Range (ATR)
- OMH 0.22
- GNPX 0.06
- MACD
- OMH -0.07
- GNPX 0.00
- Stochastic Oscillator
- OMH 23.38
- GNPX 31.23
About GNPX Genprex Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.